Registry-listed formulations

iratumumab · mesh:C510955

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 1 completed trials

    Completion Rate
    100%(1/1)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1/2
    1
    100%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution1 total trials
    Phase 1/2Combined phases
    1(100.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    1 of 1 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    1

    all time

    Status Distribution
    Completed(1)

    Detailed Status

    Completed1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    1
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 1/21 (100.0%)

    Trials by Status

    completed1100%

    Recent Activity

    0 active trials
    Showing 1 of 1
    completedphase_1_2

    MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

    NCT00059995

    Clinical Trials (1)

    Showing 1 of 1 trials
    NCT00059995Phase 1/2

    MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

    Completed

    All 1 trials loaded

    Drug Details

    Intervention Type
    Biological
    Molecule Type
    Antibody
    Total Trials
    1

    External References

    ChEMBL
    CHEMBL2108612

    Names & Codes

    Research Codes

    MDX-060MDX-060 monoclonal antibody